

Preliminary safety findings: IFN-free DAA comb. with dasabuvir in chronic HCV patients

April 25 2015

Preliminary data from an ongoing study revealed today at The International Liver Congress 2015 suggest that a combination of three direct-acting antivirals (DAAs) plus dasabuvir is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. In addition, the combination led to rapid hepatitis C viral load suppression with no virological failures seen in the preliminary data from the ongoing open-label study.

In the study, treatment naïve non-cirrhotic adults with chronic HCV GT1 infection and [chronic kidney disease](#) (CKD) classified as stage 4 or stage 5, received 12 weeks of treatment with ombitasvir / paritaprevir / ritonavir and dasabuvir (3D) either with or without ribavirin. There was a 24-week post-treatment follow-up period. As of February 18 2015, 17 of a planned 20 patients in Cohort 1 had received treatment and six had completed treatment. The combination has been well tolerated to date, with no treatment-related serious adverse events, one hemoglobin decline to

Citation: Preliminary safety findings: IFN-free DAA comb. with dasabuvir in chronic HCV patients (2015, April 25) retrieved 5 May 2024 from <https://medicalxpress.com/news/2015-04-prelim-safety-ifn-free-daa-dasabuvir.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is

provided for information purposes only.